New role for FDA-approved drugs in combating antibiotic-resistant bacteria

Jourdan A. Andersson, Eric C. Fitts, Michelle L. Kirtley, Duraisamy Ponnusamy, Alex-Giovanny Peniche-Trujillo, Sara Dann-Grice, Vladimir Motin, Sadhana Chauhan, Jason A. Rosenzweig, Jian Sha, Ashok Chopra

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Antibiotic resistance in medically relevant bacterial pathogens, coupled with a paucity of novel antimicrobial discoveries, represents a pressing global crisis. Traditional drug discovery is an inefficient and costly process; however, systematic screening of Food and Drug Administration (FDA)-approved therapeutics for other indications in humans offers a rapid alternative approach. In this study, we screened a library of 780 FDA-approved drugs to identify molecules that rendered RAW 264.7 murine macrophages resistant to cytotoxicity induced by the highly virulent Yersinia pestis CO92 strain. Of these compounds, we identified 94 not classified as antibiotics as being effective at preventing Y. pestis-induced cytotoxicity. A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo. Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y. pestis and having no modulating effect on crucial Y. pestis virulence factors. These findings suggested that DXP, AXPN, and TFP may modulate host cell pathways necessary for disease pathogenesis. Finally, to further assess the broad applicability of drugs identified from in vitro screens, the therapeutic potential of TFP, the most efficacious drug in vivo, was evaluated in murine models of Salmonella enterica serovar Typhimurium and Clostridium difficile infections. In both models, TFP treatment resulted in increased survivability of infected animals. Taken together, these results demonstrate the broad applicability and potential use of nonantibiotic FDA-approved drugs to combat respiratory and gastrointestinal bacterial pathogens.

Original languageEnglish (US)
Pages (from-to)3717-3729
Number of pages13
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

United States Food and Drug Administration
Yersinia pestis
Trifluoperazine
Anti-Bacterial Agents
Bacteria
Amoxapine
Doxapram
Pharmaceutical Preparations
Clostridium Infections
Salmonella enterica
Plague
Clostridium difficile
Virulence Factors
Drug Discovery
Microbial Drug Resistance
Libraries
Macrophages
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

New role for FDA-approved drugs in combating antibiotic-resistant bacteria. / Andersson, Jourdan A.; Fitts, Eric C.; Kirtley, Michelle L.; Ponnusamy, Duraisamy; Peniche-Trujillo, Alex-Giovanny; Dann-Grice, Sara; Motin, Vladimir; Chauhan, Sadhana; Rosenzweig, Jason A.; Sha, Jian; Chopra, Ashok.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 6, 01.06.2016, p. 3717-3729.

Research output: Contribution to journalArticle

Andersson, Jourdan A. ; Fitts, Eric C. ; Kirtley, Michelle L. ; Ponnusamy, Duraisamy ; Peniche-Trujillo, Alex-Giovanny ; Dann-Grice, Sara ; Motin, Vladimir ; Chauhan, Sadhana ; Rosenzweig, Jason A. ; Sha, Jian ; Chopra, Ashok. / New role for FDA-approved drugs in combating antibiotic-resistant bacteria. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 6. pp. 3717-3729.
@article{4ad9b538ac194583a2bd31e3d86f1ed9,
title = "New role for FDA-approved drugs in combating antibiotic-resistant bacteria",
abstract = "Antibiotic resistance in medically relevant bacterial pathogens, coupled with a paucity of novel antimicrobial discoveries, represents a pressing global crisis. Traditional drug discovery is an inefficient and costly process; however, systematic screening of Food and Drug Administration (FDA)-approved therapeutics for other indications in humans offers a rapid alternative approach. In this study, we screened a library of 780 FDA-approved drugs to identify molecules that rendered RAW 264.7 murine macrophages resistant to cytotoxicity induced by the highly virulent Yersinia pestis CO92 strain. Of these compounds, we identified 94 not classified as antibiotics as being effective at preventing Y. pestis-induced cytotoxicity. A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo. Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y. pestis and having no modulating effect on crucial Y. pestis virulence factors. These findings suggested that DXP, AXPN, and TFP may modulate host cell pathways necessary for disease pathogenesis. Finally, to further assess the broad applicability of drugs identified from in vitro screens, the therapeutic potential of TFP, the most efficacious drug in vivo, was evaluated in murine models of Salmonella enterica serovar Typhimurium and Clostridium difficile infections. In both models, TFP treatment resulted in increased survivability of infected animals. Taken together, these results demonstrate the broad applicability and potential use of nonantibiotic FDA-approved drugs to combat respiratory and gastrointestinal bacterial pathogens.",
author = "Andersson, {Jourdan A.} and Fitts, {Eric C.} and Kirtley, {Michelle L.} and Duraisamy Ponnusamy and Alex-Giovanny Peniche-Trujillo and Sara Dann-Grice and Vladimir Motin and Sadhana Chauhan and Rosenzweig, {Jason A.} and Jian Sha and Ashok Chopra",
year = "2016",
month = "6",
day = "1",
doi = "10.1128/AAC.00326-16",
language = "English (US)",
volume = "60",
pages = "3717--3729",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - New role for FDA-approved drugs in combating antibiotic-resistant bacteria

AU - Andersson, Jourdan A.

AU - Fitts, Eric C.

AU - Kirtley, Michelle L.

AU - Ponnusamy, Duraisamy

AU - Peniche-Trujillo, Alex-Giovanny

AU - Dann-Grice, Sara

AU - Motin, Vladimir

AU - Chauhan, Sadhana

AU - Rosenzweig, Jason A.

AU - Sha, Jian

AU - Chopra, Ashok

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Antibiotic resistance in medically relevant bacterial pathogens, coupled with a paucity of novel antimicrobial discoveries, represents a pressing global crisis. Traditional drug discovery is an inefficient and costly process; however, systematic screening of Food and Drug Administration (FDA)-approved therapeutics for other indications in humans offers a rapid alternative approach. In this study, we screened a library of 780 FDA-approved drugs to identify molecules that rendered RAW 264.7 murine macrophages resistant to cytotoxicity induced by the highly virulent Yersinia pestis CO92 strain. Of these compounds, we identified 94 not classified as antibiotics as being effective at preventing Y. pestis-induced cytotoxicity. A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo. Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y. pestis and having no modulating effect on crucial Y. pestis virulence factors. These findings suggested that DXP, AXPN, and TFP may modulate host cell pathways necessary for disease pathogenesis. Finally, to further assess the broad applicability of drugs identified from in vitro screens, the therapeutic potential of TFP, the most efficacious drug in vivo, was evaluated in murine models of Salmonella enterica serovar Typhimurium and Clostridium difficile infections. In both models, TFP treatment resulted in increased survivability of infected animals. Taken together, these results demonstrate the broad applicability and potential use of nonantibiotic FDA-approved drugs to combat respiratory and gastrointestinal bacterial pathogens.

AB - Antibiotic resistance in medically relevant bacterial pathogens, coupled with a paucity of novel antimicrobial discoveries, represents a pressing global crisis. Traditional drug discovery is an inefficient and costly process; however, systematic screening of Food and Drug Administration (FDA)-approved therapeutics for other indications in humans offers a rapid alternative approach. In this study, we screened a library of 780 FDA-approved drugs to identify molecules that rendered RAW 264.7 murine macrophages resistant to cytotoxicity induced by the highly virulent Yersinia pestis CO92 strain. Of these compounds, we identified 94 not classified as antibiotics as being effective at preventing Y. pestis-induced cytotoxicity. A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo. Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y. pestis and having no modulating effect on crucial Y. pestis virulence factors. These findings suggested that DXP, AXPN, and TFP may modulate host cell pathways necessary for disease pathogenesis. Finally, to further assess the broad applicability of drugs identified from in vitro screens, the therapeutic potential of TFP, the most efficacious drug in vivo, was evaluated in murine models of Salmonella enterica serovar Typhimurium and Clostridium difficile infections. In both models, TFP treatment resulted in increased survivability of infected animals. Taken together, these results demonstrate the broad applicability and potential use of nonantibiotic FDA-approved drugs to combat respiratory and gastrointestinal bacterial pathogens.

UR - http://www.scopus.com/inward/record.url?scp=84973531811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973531811&partnerID=8YFLogxK

U2 - 10.1128/AAC.00326-16

DO - 10.1128/AAC.00326-16

M3 - Article

C2 - 27067323

AN - SCOPUS:84973531811

VL - 60

SP - 3717

EP - 3729

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -